BMO Capital raised the firm’s price target on BrightSpring Health (BTSG) to $60 from $52 and keeps an Outperform rating on the shares. The magnitude of the company’s Q1 earnings beat was the largest yet while the management also raised its outlook for revenue and EBITDA in FY26, the analyst tells investors in a research note. The backdrop for Specialty Pharmacy remains encouraging, with BrightSpring still expecting to win 20 Limited Distribution Drugs in 2026 and benefit from multiple large generic conversions over the coming quarters, BMO added.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health price target raised to $64 from $53 at Stephens
- BrightSpring Health price target raised to $65 from $55 at BTIG
- BrightSpring Health price target raised to $61 from $50 at Wells Fargo
- BrightSpring Health price target raised to $60 from $55 at KeyBanc
- BrightSpring Earnings Call Highlights Strong Growth Momentum